Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 16

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 16
---
 above offerings and shares of Common Stock underlying the Investor Warrants issued by the Company to these investors are included in this registration statement of which this Prospectus is a part thereof. Corporate Information Our principal executive offices are located at Azrieli Business Center, 8 Mediant HaYehudim, Herzliya, Israel, and our phone number is 1 800 519-1687. Our website is www.reviumrx.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this Prospectus, and you should not consider information on our website to be part of this Prospectus. Implications of Being an Emerging Growth Company As a company with less than US$1.07 billion in revenue for our last fiscal year, the Company qualifies as an “emerging growth company” pursuant to the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable generally to public companies. These provisions include, but are not limited to:

| ● | being permitted to present                                                                                                     
 only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial 
 Condition and Results of Operations in our SEC filings;                                                                        |

| ● | not being required to comply                                                        
 with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; |

| ● | reduced disclosure obligations                                                                          
 regarding executive compensation in periodic reports, proxy statements and registration statements; and |

| ● | exemptions from the requirements                                                                                                         
 of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously 
 approved.                                                                                                                                |

The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. The Company has elected to use the extended transition period under the JOBS Act. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. The Company will remain an emerging growth company until the earliest of (a) the last day of the fiscal year during which it has total annual gross revenues of less than US$ 1.235 billion; (b) the last day of its fiscal year following the fifth anniversary of the completion of this initial public offering; (c